These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33771843)

  • 1. Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice.
    Carral San Laureano F; Tomé Fernández-Ladreda M; Jiménez Millán AI; García Calzado C; Ayala Ortega MDC
    J Investig Med; 2021 Jun; 69(5):983-988. PubMed ID: 33771843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
    Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
    Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
    Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
    Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes.
    Oya J; Nakagami T; Hasegawa Y; Katamine A; Kondo Y; Babazono T
    J Diabetes Investig; 2021 Nov; 12(11):1983-1991. PubMed ID: 33938149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats.
    Gilor C; Culp W; Ghandi S; do Carmo Emidio E Silva JA; Ladhar A; Hulsebosch SE
    Domest Anim Endocrinol; 2019 Oct; 69():19-29. PubMed ID: 31280022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
    Mathieu C; Hollander P; Miranda-Palma B; Cooper J; Franek E; Russell-Jones D; Larsen J; Tamer SC; Bain SC;
    J Clin Endocrinol Metab; 2013 Mar; 98(3):1154-62. PubMed ID: 23393185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
    Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
    Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.
    Nakamura T; Sakaguchi K; So A; Nakajima S; Takabe M; Komada H; Okuno Y; Hirota Y; Nakamura T; Iida K; Kajikawa M; Nagata M; Ogawa W; Seino S
    Diabetologia; 2015 Sep; 58(9):2013-9. PubMed ID: 26044206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study.
    Lualdi C; Silverii A; Dicembrini I; Pala L; Monami M; Mannucci E
    J Endocrinol Invest; 2019 Mar; 42(3):319-326. PubMed ID: 29987755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus - outcomes from cross-over open-label randomized trial.
    Cindro PV; Krnić M; Modun D; Smajić B; Vuković J
    BMC Endocr Disord; 2021 Apr; 21(1):86. PubMed ID: 33926446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.
    Weatherall J; Bloudek L; Buchs S
    Curr Med Res Opin; 2017 Feb; 33(2):231-238. PubMed ID: 27764979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
    Ratner RE; Gough SC; Mathieu C; Del Prato S; Bode B; Mersebach H; Endahl L; Zinman B
    Diabetes Obes Metab; 2013 Feb; 15(2):175-84. PubMed ID: 23130654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang Y; Long C; Li T; Chen Q
    Front Endocrinol (Lausanne); 2022; 13():890090. PubMed ID: 35721710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
    Heise T; Kaplan K; Haahr HL
    J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
    Lüdemann J; Milek K; Wilhelm B; Segner A; Jaeckel E
    MMW Fortschr Med; 2014 Oct; 156 Suppl 3():89-97. PubMed ID: 25507175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
    Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y
    Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
    Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
    Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.
    Shimoda S; Sakamoto W; Hokamura A; Matsuo Y; Sekigami T; Ichimori S; Iwashita S; Ishii N; Otsu K; Yoshimura R; Nishiyama T; Sakaguchi M; Nishida K; Araki E
    Endocr J; 2019 Aug; 66(8):745-752. PubMed ID: 31308304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.